Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Palvella Therapeutics, retaining the price target of $150.00.

Sam Slutsky has given his Buy rating due to a combination of factors tied to both the clinical and commercial outlook for QTORIN 3.9% rapamycin in microcystic lymphatic malformations (MLMs) and cutaneous venous malformations (CVMs). His survey of 29 U.S. dermatologists and hematologist‑oncologists shows that rapamycin/sirolimus and sclerotherapy are already core components of MLM treatment, with many physicians favoring topical over oral formulations, signaling that prescribers are comfortable with topical mTOR inhibition. Respondents indicated that roughly half of MLM patients have disease where a topical therapy is clinically appropriate, suggesting a sizable addressable segment for QTORIN. For CVMs, while sclerotherapy and laser dominate first-line management, rapamycin/sirolimus is widely used as a key second‑line option, and physicians estimate that a meaningful proportion of these patients present with skin‑dominant disease that could benefit from a topical approach.
More than half of surveyed physicians described themselves as excited or very excited about a high‑concentration topical rapamycin product for MLMs and/or CVMs, indicating strong potential uptake if QTORIN is approved. Slutsky also notes that the survey was conducted across a broad prescriber base rather than only high‑volume specialty centers, which likely makes the demand estimates conservative and reinforces the robustness of the perceived opportunity. When paired with Palvella’s current capitalization profile, including its fully diluted share count and cash runway, he concludes that the market is undervaluing the commercial potential of QTORIN relative to the size and accessibility of the target patient populations. Taken together, the established use of rapamycin in these indications, the clear clinical niche for a topical high‑strength formulation, and the favorable physician sentiment underpin his Buy recommendation on Palvella Therapeutics.

In another report released on January 12, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $108.00 price target.